Advancing targeted co-stimulation with antibody-fusion proteins by introducing TNF superfamily members in a single-chain format

An optimized antibody-single-chain TRAIL fusion protein for cancer therapy

(2016) Martin Siegemund et al.   mAbs

Principles of antibody-mediated TNF receptor activation

(2015) H Wajant   CELL DEATH AND DIFFERENTIATION

Binding Studies of TNF Receptor Superfamily (TNFRSF) Receptors on Intact Cells

(2015) Isabell Lang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Antibody fusions with immunomodulatory proteins for cancer therapy

(2015) Dafne Müller   PHARMACOLOGY & THERAPEUTICS

Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS

(2015) Miguel F. Sanmamed et al.   SEMINARS IN ONCOLOGY

SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines

(2014) Rajesh K Sharma et al.   Expert Review of Vaccines

Tumor targeting properties of antibody fusion proteins based on different members of the murine tumor necrosis superfamily

(2014) Teresa Hemmerle et al.   JOURNAL OF BIOTECHNOLOGY

Single-Chain TNF, a TNF Derivative with Enhanced Stability and Antitumoral Activity

(2014) A. Krippner-Heidenreich et al.   JOURNAL OF IMMUNOLOGY

Mechanistic Basis for Functional Promiscuity in the TNF and TNF Receptor Superfamilies: Structure of the LIGHT:DcR3 Assembly

(2014) Weifeng Liu et al.   STRUCTURE

Trial Watch

(2014) Fernando Aranda et al.   OncoImmunology

Evaluating combinations of costimulatory antibody–ligand fusion proteins for targeted cancer immunotherapy

(2013) Nora Hornig et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Agonist Antibodies to TNFR Molecules That Costimulate T and NK Cells

(2013) I. Melero et al.   CLINICAL CANCER RESEARCH

Tetravalent Antibody-scTRAIL Fusion Proteins with Improved Properties

(2013) O. Seifert et al.   MOLECULAR CANCER THERAPEUTICS

Clinical targeting of the TNF and TNFR superfamilies

(2013) Michael Croft et al.   NATURE REVIEWS DRUG DISCOVERY

Antibody–cytokine fusion proteins

(2012) Roland E. Kontermann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

An In Vivo Immunotherapy Screen of Costimulatory Molecules Identifies Fc-OX40L as a Potent Reagent for the Treatment of Established Murine Gliomas

(2012) K. A. Murphy et al.   CLINICAL CANCER RESEARCH

Combination of a Bispecific Antibody and Costimulatory Antibody-Ligand Fusion Proteins for Targeted Cancer Immunotherapy

(2012) Nora Hornig et al.   JOURNAL OF IMMUNOTHERAPY

Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity

(2012) M Siegemund et al.   Cell Death & Disease

Treatment with anti-CD137 mAbs causes intense accumulations of liver T cells without selective antitumor immunotherapeutic effects in this organ

(2010) Juan Dubrot et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen

(2010) Claudia Bluemel et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies

(2010) Paolo A. Ascierto et al.   SEMINARS IN ONCOLOGY

Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins

(2010) B Schneider et al.   Cell Death & Disease

Sequence, structure, function, immunity: structural genomics of costimulation

(2009) Kausik Chattopadhyay et al.   IMMUNOLOGICAL REVIEWS

The Structure of the Trimer of Human 4-1BB Ligand Is Unique among Members of the Tumor Necrosis Factor Superfamily

(2009) Eun-Young Won et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Trimer Stabilization, Oligomerization, and Antibody-Mediated Cell Surface Immobilization Improve the Activity of Soluble Trimers of CD27L, CD40L, 41BBL, and Glucocorticoid-Induced TNF Receptor Ligand

(2009) A. Wyzgol et al.   JOURNAL OF IMMUNOLOGY

Fc-mOX40L Fusion Protein Produces Complete Remission and Enhanced Survival in 2 Murine Tumor Models

(2009) Rebecca E. Sadun et al.   JOURNAL OF IMMUNOTHERAPY

A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity

(2009) Rich-Henry Schabowsky et al.   VACCINE

A Novel Antibody–4-1BBL Fusion Protein for Targeted Costimulation in Cancer Immunotherapy

(2008) Dafne Müller et al.   JOURNAL OF IMMUNOTHERAPY